Bernd Hoppe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6281315/publications.pdf

Version: 2024-02-01

88 papers	4,566 citations	94381 37 h-index	106281 65 g-index
93 all docs	93 docs citations	93 times ranked	3202 citing authors

#	Article	IF	Citations
1	The primary hyperoxalurias. Kidney International, 2009, 75, 1264-1271.	2.6	314
2	History, epidemiology and regional diversities of urolithiasis. Pediatric Nephrology, 2010, 25, 49-59.	0.9	299
3	Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrology Dialysis Transplantation, 2012, 27, 1729-1736.	0.4	266
4	An update on primary hyperoxaluria. Nature Reviews Nephrology, 2012, 8, 467-475.	4.1	239
5	The Primary Hyperoxalurias. Journal of the American Society of Nephrology: JASN, 2001, 12, 1986-1993.	3.0	197
6	Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatric Nephrology, 2010, 25, 403-413.	0.9	187
7	A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatric Nephrology, 2003, 18, 986-991.	0.9	169
8	Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrology Dialysis Transplantation, 2011, 26, 3609-3615.	0.4	139
9	Nephrocalcinosis and urolithiasis in children. Kidney International, 2011, 80, 1278-1291.	2.6	125
10	Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. Journal of the American Society of Nephrology: JASN, 2014, 25, 2366-2375.	3.0	124
11	Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatric Nephrology, 1993, 7, 207-211.	0.9	123
12	Vitamin B6 in Primary Hyperoxaluria I. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 468-477.	2.2	110
13	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alportâ€™s syndrome. Kidney International, 2020, 97, 1275-1286.	2.6	94
14	A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis, 2018, 46, 313-323.	1.2	83
15	Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 761-768.	3.0	78
16	Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohnâ€™s disease. Pediatric Nephrology, 2012, 27, 1103-1109.	0.9	71
17	Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. European Journal of Human Genetics, 2013, 21, 162-172.	1.4	71
18	A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatric Nephrology, 2017, 32, 781-790.	0.9	66

#	Article	IF	Citations
19	Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?. Urological Research, 2005, 33, 372-375.	1.5	63
20	Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opinion on Investigational Drugs, 2013, 22, 117-129.	1.9	61
21	Complement Mutations in Diacylglycerol Kinase-Îµâ€“Associated Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1611-1619.	2.2	61
22	Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney International, 2019, 96, 1389-1399.	2.6	61
23	Absorptive Hyperoxaluria Leads to an Increased Risk for Urolithiasis or Nephrocalcinosis in Cystic Fibrosis. American Journal of Kidney Diseases, 2005, 46, 440-445.	2.1	60
24	Urinary Calcium Oxalate Saturation in Healthy Infants and Children. Journal of Urology, 1997, 158, 557-559.	0.2	59
25	Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Frontiers in Bioscience - Landmark, 2003, 8, e437-443.	3.0	59
26	Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney International, 1998, 54, 921-925.	2.6	54
27	Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. Journal of Clinical Investigation, 2019, 129, 4506-4522.	3.9	54
28	Nephrocalcinosis in preterm infants: a single center experience. Pediatric Nephrology, 2002, 17, 264-268.	0.9	51
29	Eculizumab in Pediatric Dense Deposit Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1773-1782.	2.2	51
30	Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography: Technical Note. Kidney International, 1998, 53, 1348-1352.	2.6	49
31	Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction. American Journal of Human Genetics, 2019, 104, 994-1006.	2.6	47
32	Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney International, 2022, 101, 626-634.	2.6	47
33	Diagnostic and therapeutic strategies in hyperoxaluria: a plea for early intervention. Nephrology Dialysis Transplantation, 2004, 19, 39-42.	0.4	46
34	Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrology, 2015, 16, 22.	0.8	46
35	Liver cell transplantation in severe infantile oxalosis--a potential bridging procedure to orthotopic liver transplantation?. Nephrology Dialysis Transplantation, 2012, 27, 2984-2989.	0.4	43
36	Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney International, 2003, 63, 2194-2199.	2.6	41

#	Article	IF	Citations
37	Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease. Journal of Pediatrics, 2018, 199, 22-28.e6.	0.9	39
38	Management of bone disease in cystinosis: Statement from an international conference. Journal of Inherited Metabolic Disease, 2019, 42, 1019-1029.	1.7	39
39	Urolithiasis and Nephrocalcinosis in Childhood. , 2008, , 499-525.		38
40	Reduction of Plasma Oxalate Levels by Oral Application of Oxalobacter formigenes in 2 Patients With Infantile Oxalosis. American Journal of Kidney Diseases, 2011, 58, 453-455.	2.1	38
41	Ultrasound-Guided Percutaneous Renal Biopsy in 295 Children and Adolescents: Role of Ultrasound and Analysis of Complications. PLoS ONE, 2014, 9, e114737.	1.1	37
42	Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. Clinical Infectious Diseases, 2017, 64, 1637-1643.	2.9	35
43	Novel therapeutic approaches in primary hyperoxaluria. Expert Opinion on Emerging Drugs, 2018, 23, 349-357.	1.0	35
44	Kidney Stones in Primary Hyperoxaluria: New Lessons Learnt. PLoS ONE, 2013, 8, e70617.	1.1	30
45	Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatric Nephrology, 2017, 32, 131-137.	0.9	29
46	Nephrolithiasis and Nephrocalcinosis in Childhoodâ€"Risk Factor-Related Current and Future Treatment Options. Frontiers in Pediatrics, 2018, 6, 98.	0.9	29
47	Genetic Risk Factors for Idiopathic Urolithiasis: A Systematic Review of the Literature and Causal Network Analysis. European Urology Focus, 2017, 3, 72-81.	1.6	27
48	Outcome of renal transplantation in small infants: a match-controlled analysis. Pediatric Nephrology, 2018, 33, 1057-1068.	0.9	27
49	A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney International, 2021, 100, 621-635.	2.6	26
50	Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study. Nephrology Dialysis Transplantation, 2021, 36, 1464-1473.	0.4	24
51	Oxalate, Citrate, and Sulfate Concentration in Human Milk Compared with Formula Preparations: Influence on Urinary Anion Excretion. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 383-386.	0.9	23
52	Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatric Nephrology, 2017, 32, 2263-2271.	0.9	22
53	The Ocular Phenotype in Primary Hyperoxaluria Type 1. American Journal of Ophthalmology, 2019, 206, 184-191.	1.7	21
54	New Aspects of Kidney Fibrosisâ€"From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814497.	1.2	21

#	Article	IF	Citations
55	Pre-emptive liver transplantation in primary hyperoxaluria type 1: A controversial issue. Pediatric Transplantation, 2000, 4, 161-164.	0.5	20
56	Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatric Nephrology, 2016, 31, 443-453.	0.9	19
57	Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry. Kidney International Reports, 2022, 7, 210-220.	0.4	19
58	Cardiorespiratory capacity in children and adolescents on maintenance haemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 3701-3708.	0.4	16
59	Metabolic profile and impact of diet in patients with primary hyperoxaluria. International Urology and Nephrology, 2018, 50, 1583-1589.	0.6	16
60	Inherited conditions resulting in nephrolithiasis. Current Opinion in Pediatrics, 2020, 32, 273-283.	1.0	16
61	Plasma oxalate: comparison of methodologies. Urolithiasis, 2020, 48, 473-480.	1.2	16
62	Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatric Nephrology, 2009, 24, 1997-2003.	0.9	14
63	Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatric Nephrology, 2017, 32, 1221-1232.	0.9	14
64	Update on Hereditary Kidney Stone Disease and Introduction of a New Clinical Patient Registry in Germany. Frontiers in Pediatrics, 2018, 6, 47.	0.9	14
65	Targeting kidney inflammation as a new therapy for primary hyperoxaluria?. Nephrology Dialysis Transplantation, 2019, 34, 908-914.	0.4	14
66	Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. Journal of Molecular Medicine, 2018, 96, 621-630.	1.7	13
67	Improving Treatment Options for Primary Hyperoxaluria. Drugs, 2022, 82, 1077-1094.	4.9	13
68	Inhomogeneous Longitudinal Cardiac Rotation and Impaired Left Ventricular Longitudinal Strain in Children and Young Adults with Endâ€Stage Renal Failure Undergoing Hemodialysis. Echocardiography, 2015, 32, 1250-1260.	0.3	11
69	Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study. Pediatric Nephrology, 2019, 34, 2591-2600.	0.9	11
70	Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis. Pediatric Nephrology, 2020, 35, 1121-1124.	0.9	11
71	Combined liverâ€“kidney transplantation for hyperoxaluria type II?. Pediatric Transplantation, 2014, 18, 237-239.	0.5	10
72	Is stiripentol truly effective for treating primary hyperoxaluria?. CKJ: Clinical Kidney Journal, 2021, 14, 442-444.	1.4	10

#	Article	IF	Citations
73	Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function. Pediatric Nephrology, 2020, 35, 1227-1233.	0.9	9
74	Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. American Journal of Nephrology, 2016, 43, 293-303.	1.4	7
75	Precise variant interpretation, phenotype ascertainment, and genotypeâ€“phenotype correlation of children in the <scp>EARLY PROâ€TECT</scp> Alport trial. Clinical Genetics, 2021, 99, 143-156.	1.0	7
76	Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. Kidney International Reports, 2022, 7, 1608-1618.	0.4	7
77	A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O85-O88.	0.6	6
78	Examination of the eye and retinal alterations in primary hyperoxaluria type 1. Nephrology Dialysis Transplantation, 2020, , .	0.4	5
79	Urinary excretion of calcium, magnesium, phosphate, citrate, oxalate, and uric acid by healthy schoolchildren using a 12-h collection protocol. Pediatric Nephrology, 2014, 29, 2065-2067.	0.9	3
80	Endurance training during maintenance hemodialysis in pediatric and adolescent patientsâ€”theory and best practice suggestions. Pediatric Nephrology, 2020, 35, 595-602.	0.9	3
81	Diet-related urine collections: assistance in categorization of hyperoxaluria. Urolithiasis, 2022, 50, 141-148.	1.2	3
82	Extracorporeal membrane oxygenation support in a newborn with lower urinary tract obstruction and pulmonary hypoplasia: a case report. Journal of Medical Case Reports, 2018, 12, 210.	0.4	2
83	Endurance-oriented training program with children and adolescents on maintenance hemodialysis to enhance dialysis efficacyâ€”DiaSport. Pediatric Nephrology, 2021, 36, 3923-3932.	0.9	2
84	Oxabact: truly a new treatment option in patients with (primary) hyperoxaluria?. Expert Opinion on Orphan Drugs, 2013, 1, 177-184.	0.5	1
85	Primary hyperoxaluria â€“ An update. Journal of Pediatric Biochemistry, 2015, 04, 101-110.	0.2	0
86	Nephrocalcinosis in childhood. Journal of Pediatric Biochemistry, 2015, 04, 111-118.	0.2	0
87	Genetische Nierensteinerkrankungen. Medizinische Genetik, 2018, 30, 438-447.	0.1	0
88	Adverse effects of hormone preparations and related medications used to treat disorders of bone and mineral metabolism. Pediatric Endocrinology Reviews, 2004, 2 Suppl 1, 146-52.	1.2	0